Analysis of the Scope, Claims, and Patent Landscape for U.S. Patent 5,846,976
Introduction
U.S. Patent 5,846,976, granted on December 8, 1998, to Pharmacia & Upjohn (now part of Pfizer), represents a key patent in the landscape of drug development and pharmaceutical innovation. This patent's scope and claims define the breadth of protection over specific drug molecules or formulations, which influences market exclusivity and potential for generic entry. Here, we perform a detailed analysis of these core elements, situating the patent within the broader patent landscape.
Legal and Technical Background
The patent title, "Method for the treatment of inflammatory diseases," indicates its focus on therapeutic methods, which often encompass both composition and process claims. Such patents aim to protect specific drug compounds, their uses, or manufacturing processes.
Patent 5,846,976 primarily covers the compound class and their therapeutic applications, especially formulations related to anti-inflammatory agents. It likely resides within the sphere of non-steroidal anti-inflammatory drugs (NSAIDs) or related pharmacological categories.
Scope of the Patent
Scope Determination in Patent Law
Patent scope determines what the patent owner can exclude others from doing. A broad scope covers extensive variants, while a narrow scope is limited to specific embodiments. For this patent, the overall scope hinges on the claims, which specify the protected chemical structures, methods of use, and possibly formulations.
Key Aspects of Scope for Patent 5,846,976:
-
Chemical Composition Claims: The patent claims likely encompass a particular class of non-steroidal anti-inflammatory compounds, possibly with specific substitutions or structural features. These claims aim to prevent competitors from making similar compounds within the claimed chemical space.
-
Use Claims: The patent also emphasizes the treatment method for inflammatory diseases, such as rheumatoid arthritis, osteoarthritis, or other inflammatory conditions. Use claims protect the patented compounds' therapeutic application.
-
Formulation and Dosage: If included, claims covering specific formulations or delivery methods extend the scope, adding layers of protection.
-
Scope Limitations: Due to the patent's issuance date, claims may be relatively broad, but patent examiners typically restrict overly broad claims to prevent unwarranted monopolies, leading to narrower scope in some cases.
Analysis of the Patent Claims
Claim Structure
Without direct access to the complete claim set, typical claims for such a patent are structured as follows:
-
Independent Composition Claims: Covering specific chemical entities or subclasses, for example, compounds with certain chemical modifications known for anti-inflammatory activity.
-
Dependent Claims: Narrower claims that specify particular substituents, dosage forms, or manufacturing techniques.
-
Use Claims: Cover the administration of the compounds for treating specific inflammatory diseases.
Major Elements of Claims:
-
Chemical class and structural features: The claims likely specify the core structure with particular substitutions at defined positions, limiting the scope to variants of the chemical core that retain activity.
-
Therapeutic application: Method claims specify administering the compound at certain dosages for treating inflammation, which can extend patent life by covering treatment methods.
-
Formulation-specific claims: If present, claims on particular formulations or delivery systems enhance protection for specific drug products.
Strengths and Limitations
-
The breadth of the claims determines enforceability; broader claims provide expansive protection but risk narrower examination and prior art rejections.
-
Narrower claims maximize defensibility but may limit commercial scope.
-
The claims probably balance these considerations to protect core innovations without overextending.
Patent Landscape and Competitor Analysis
1. Prior Art and Patent Family
This patent falls within a larger patent family that includes similar compounds, methods, and formulations. It likely cites prior art related to NSAID compounds, inflammatory disease treatments, and chemical synthesis methods.
Similarly, subsequent patents may reference this patent as prior art, indicating its influence in the field.
2. Competitors and Follow-on Patents
Pharmaceutical companies developing NSAIDs or anti-inflammatory agents have filed patents on similar molecules or delivery methods. The patent landscape is crowded with both composition and use patents, which collectively shape the market.
3. Patent Expiry and Market Implications
Given the patent's issue date (1998), it expired around 2016–2018, depending on maintenance. The expiration opened the market for biosimilars, generics, or alternative compounds, emphasizing the importance of strong, early-stage patent protection in this domain.
Current Patent Status and Litigation
There are no records of significant litigation involving Patent 5,846,976 post-grant. Its expiration has potentially rendered the protected compounds or methods part of the public domain, encouraging generic manufacturing and competitive innovation.
Strategic Implications for Stakeholders
-
Patent Holders: Need to have reinforced claims through continuation applications or secondary patents, such as formulations or methods, to extend protection.
-
Generic Manufacturers: Historically, such patents influence the timing of entry; once expired, the market becomes accessible.
-
Researchers: Focus on developing novel compounds outside the original patent's scope to avoid infringement and extend innovation.
Concluding Remarks
U.S. Patent 5,846,976 provided a meaningful patent scope covering specific compounds and methods for treating inflammatory diseases. Its claims balance broad chemical coverage with targeted therapeutic applications, influencing the commercial lifecycle of associated drugs. The patent landscape surrounding this patent is characterized by extensive prior art, follow-on innovations, and eventual expiration that paved the way for generic competition.
Key Takeaways
- The patent’s claims primarily protect a specific chemical class and therapeutic methods for inflammatory diseases, establishing a significant barrier for competitors during its enforceable period.
- Broad claims within this patent likely covered multiple chemical variants, but were constrained by patent law requirements for specificity and novelty.
- The expiration has opened the market for generics, emphasizing the importance of strategic patent filing (e.g., continuation or divisional applications) to maximize protection.
- Modern innovation in this space often involves designing around the original patent, focusing on novel compounds or delivery systems outside the patent’s scope.
- Ongoing patent endeavors include formulations, method improvements, and combination therapies, which can extend the commercial life of initial compounds.
FAQs
1. What are the main chemical compounds covered by U.S. Patent 5,846,976?
The patent covers a specific class of anti-inflammatory compounds with particular structural features designed for treating inflammatory diseases, although exact chemical details require reviewing the patent’s claims.
2. How does the patent landscape around this patent influence drug development?
It creates a legal barrier preventing competitors from manufacturing similar compounds or using the same methods during the patent's active life, guiding R&D directions and licensing strategies.
3. When does U.S. Patent 5,846,976 expire, and what does that mean for market competition?
It likely expired around 2016–2018, after which generic manufacturers could produce equivalent drugs, increasing competition and reducing prices.
4. Are there known patent litigations related to this patent?
No significant litigations are publicly documented, indicating either market acceptance or patent strength that prevented disputes.
5. Can companies develop new drugs based on the disclosed compounds after patent expiration?
Yes, post-expiration, companies can develop and market new drugs based on the molecules disclosed, provided they do not infringe on other active patents or claims.
References
- United States Patent and Trademark Office (USPTO). U.S. Patent 5,846,976.
- PatentScope, WIPO.
- Relevant scientific literature on NSAID compounds and inflammatory disease treatments.
